Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients.

Szczegóły
Abstrakt

Tytuł:: Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients.
Autorzy:: Swerdlow NR; Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, USA. .
Bhakta SG; Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, USA.
Talledo J; Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, USA.
Benster L; Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, USA.
Kotz J; Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, USA.
Lavadia M; Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, USA.
Light GA; Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, USA.; VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
Źródło:: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2019 Dec; Vol. 44 (13), pp. 2277-2284. Date of Electronic Publication: 2019 Aug 24.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2003- : London : Nature Publishing Group
Original Publication: [New York, NY] : Elsevier, [c1987-
MeSH Terms:: Schizophrenic Psychology*
Amphetamine/*administration & dosage
Antipsychotic Agents/*therapeutic use
Dopamine Agents/*administration & dosage
Schizophrenia/*diagnosis
Adult ; Amphetamine/adverse effects ; Blood Pressure/drug effects ; Female ; Heart Rate/drug effects ; Humans ; Male ; Middle Aged ; Risk Factors ; Schizophrenia/drug therapy
References:: Friedhoff AJ, VanWinkle E. Conversion of dopamine to 3,4-Dimethoxyphenylacetic acid in schizophrenia patients. Nature. 1963;199(Sep 28):1271–2. (PMID: 10.1038/1991271a0)
van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharm Ther. 1966;160:492–4.
Snyder SH. Amphetamine psychosis: a “model” schizophrenia mediated by catecholamines. Am J Psychiatry. 1973;130:61–7. (PMID: 10.1176/ajp.130.1.61)
Stevens J. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973;29:177–89. (PMID: 10.1001/archpsyc.1973.04200020023003)
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549–62. (PMID: 10.1093/schbul/sbp006)
Swerdlow NR. Are we studying and treating schizophrenia correctly? Schizophr Res. 2011;130:1–10. (PMID: 10.1016/j.schres.2011.05.004)
Ursini G, Punzi G, Chen Q, Marenco S, Robinson JF, Porcelli A, et al. Convergence of placenta biology and genetic risk for schizophrenia. Nat Med. 2018;24:792–801. (PMID: 10.1038/s41591-018-0021-y)
Creese I, Burt DR, Snyder SH. Dopamine receptors and average clinical doses. Science. 1976;192:481–3. (PMID: 10.1126/science.3854)
Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol. 2016;30:428–35. (PMID: 10.1177/0269881116636120)
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
Randrup A, Munkvad I. Influence of amphetamines on animal behaviour: stereotypy, functional impairment and possible animal-human correlations. Psychiatr Neurol Neurochir. 1972;75(May-Jun):193–202. (PMID: 4625013)
Antelman SM, Gershon S. Clinical application of time-dependent sensitization to antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:65–78. (PMID: 10.1016/S0278-5846(97)00098-5)
Wallis GG, McHarg JF, Scott OC. Acute psychosis caused by dextro-amphetamine. Br Med J. 1949;2:1394. (PMID: 10.1136/bmj.2.4641.1394)
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380:1128–38. (PMID: 10.1056/NEJMoa1813751)
Swerdlow NR, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, et al. Amphetamine enhances gains in auditory discrimination training in adult schizophrenia patients. Schizophr Bull. 2017;43:872–80. (PMID: 10.1093/schbul/sbx021.182)
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76. (PMID: 10.1093/schbul/13.2.261)
Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City, IA: University of Iowa; 1984a.
Andreasen NC. The scale for the assessment of positive symptoms (SAPS). Iowa City, IA: University of Iowa; 1984b.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812. (PMID: 10.2466/pr0.1962.10.3.799)
Rapaport MH, Bazetta J, McAdams LA, Patterson J, Jeste DV. Validation of the scale of functioning in older outpatients with schizophrenia. Am J Geriatr Psychiatry. 1996;4:218–28.
Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36:267–75. (PMID: 10.1016/S0033-3182(95)71666-8)
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–13. (PMID: 10.1176/appi.ajp.2007.07010042)
Swerdlow NR, Bhakta SG, Talledo JA, Franz DM, Hughes EL, Rana BK, et al. Effects of amphetamine on sensorimotor gating and neurocognition in antipsychotic-medicated schizophrenia patients. Neuropsychopharmacology. 2018a;43:708–17. (PMID: 10.1038/npp.2017.285)
Bond AJ, James DC, Lader MH. Physiological and psychological measures in anxious patients. Psychol Med. 1974;4:364–73. (PMID: 10.1017/S0033291700045803)
Norris H. The action of sedation on brain-stem oculomotor systems in man. Neuropharmacology. 1971;10:181–91. (PMID: 10.1016/0028-3908(71)90039-6)
Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, et al. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacol (Berl). 2002;161(May):189–201. (PMID: 10.1007/s00213-002-1040-3)
van Erp TG, Preda A, Nguyen D, Faziola L, Turner J, Bustillo J, et al. Converting positive and negative symptom scores between PANSS and SAPS/SANS. Schizophr Res. 2014;152:289–94. (PMID: 10.1016/j.schres.2013.11.013)
Modell W, Hussar AE. Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients: clinical and pharmacological significance. JAMA. 1965;193:275–8. (PMID: 10.1001/jama.1965.03090040019006)
Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005;77:43–58. (PMID: 10.1016/j.schres.2004.12.019)
Goldberg TE, Bigelow LB, Weinberger DR. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry. 1991;148:78–84. (PMID: 10.1176/ajp.148.1.78)
Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol. 2010;25:353–8. (PMID: 10.1002/hup.1118)
Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013;147(Jul):241–52. (PMID: 10.1016/j.schres.2013.03.019)
Lasser RA, Dirks B, Nasrallah H, Kirsch C, Gao J, Pucci ML, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013;38:2140–9. (PMID: 10.1038/npp.2013.111)
Angrist B, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacol (Berl). 1980;72:17–9. (PMID: 10.1007/BF00433802)
van Kammen DP, Bunney WE Jr, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, et al. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry. 1982;139(Aug):991–7. (PMID: 7091448)
Segal DS, Kuczenski R. An escalating dose “binge” model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci. 1997;17:2551–66. (PMID: 10.1523/JNEUROSCI.17-07-02551.1997)
Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry. 2009;65:1091–93. (PMID: 10.1016/j.biopsych.2008.12.007)
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27–35. (PMID: 10.1038/sj.mp.4002066)
Swerdlow NR, Franz DM, Benster L, Talledo J, Bhakta SG, Light GA. Early Auditory Information Processing in Schizophrenia as a Therapeutic Target: Preliminary Dose-Response Findings With Amphetamine. Proc Am Coll Neuropsychopharmacology 57th Annual Meeting 2018b, 6 December 2018. https://doi.org/10.1038/s41386-018-0268-5 .
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: L Erlbaum Assoc.; 1988.
Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis. Neuropsychopharmacol. 2016;41:419–30. (PMID: 10.1038/npp.2015.162)
Bhakta SG, Light GA, Talledo JA, Balvaneda B, Hughes E, Alvarez A, et al. Tolcapone-enhanced neurocognition in healthy adults: neural basis and predictors. Int J Neuropsychopharmacol. 2017;20:979–87. (PMID: 10.1093/ijnp/pyx074)
Substance Nomenclature:: 0 (Antipsychotic Agents)
0 (Dopamine Agents)
CK833KGX7E (Amphetamine)
Entry Date(s):: Date Created: 20190825 Date Completed: 20200708 Latest Revision: 20220417
Update Code:: 20240105
PubMed Central ID:: PMC6897898
DOI:: 10.1038/s41386-019-0495-4
PMID:: 31445502
: Czasopismo naukowe

Experimental Medicine studies in psychiatric populations test specific, mechanistic hypotheses related to the biology of mental illness, by combining well-characterized neurobiological probes and laboratory-based measures of behavioral performance and neurobiology. However, scientific inquiry through the acute administration of psychoactive drugs to patients with serious mental illness raises important ethical issues. These issues arise in studies in which the psychostimulant, amphetamine, is used as an Experimental Medicine probe in patients with schizophrenia. In this study, we summarize relevant aspects of our experience with acute, laboratory-based challenges of amphetamine in schizophrenia patients. Schizophrenia patients participated in one or more Experimental Medicine studies involving limited doses of amphetamine with clinical monitoring, over a 4-year period. Acute (within hours of ingestion; collective n = 53), subacute (three active doses over 4 weeks; n = 28), and long-term (mean = 17 months after ingestion; n = 19) effects of amphetamine ingestion were assessed. In antipsychotic (AP)-medicated schizophrenia patients, amphetamine was associated with no detrimental subjective, autonomic, or functional changes. Symptoms assessed acutely, subacutely, or long term were either unchanged or diminished. No adverse acute, subacute, or long-term consequences from the Experimental Medicine use of amphetamine in antipsychotic-medicated schizophrenia patients were detected. These findings do not address the safety or effectiveness of the use of amphetamine in unmedicated patients, or as an adjunctive treatment for schizophrenia. Indeed, it is important to distinguish evidence-based risks of symptom exacerbation in an Experimental Medicine setting vs. risks associated with long-term, daily clinical use or even misuse of amphetamine.

Informacja